The complete official prescribing information should be consulted before prescribing or dispensing erdafitinib. The following is a structured summary of current U.S. BALVERSA labeling and is not a substitute for the official label.
Indication
BALVERSA is indicated for adults with locally advanced or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Patient selection requires an FDA-approved companion diagnostic.
Limitation of use
BALVERSA is not recommended for patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
Dosage
The recommended U.S. starting dose is 8 mg once daily. In appropriate patients, the dose can increase to 9 mg once daily after 14–21 days based on phosphate levels and tolerability.
Administration
The tablets are taken orally once daily with or without food.
Dose modifications
Treatment interruption, dose reduction or discontinuation may be necessary for clinically significant adverse reactions, including ocular toxicity and hyperphosphatemia.
Major safety concerns
The prescribing information addresses:
- Ocular toxicity
- Retinal pigment epithelial detachment
- Hyperphosphatemia
- Stomatitis
- Nail disorders
- Palmar-plantar erythrodysesthesia
- Diarrhea
- Skin toxicity
- Reproductive toxicity
- Drug interactions
Contraindications
The current U.S. prescribing information should be consulted directly for the complete contraindications section and any jurisdiction-specific requirements.
Clinical pharmacology
Erdafitinib is primarily metabolized by CYP2C9 and CYP3A4 and has a reported effective half-life of approximately 59 hours in the original FDA pharmacology assessment.
Authoritative source
The latest official label should always take precedence over this website summary because regulatory labeling can change.